Booster dose
Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle Vaccine
7
Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1 2: study protocol for a multicenter, randomized, controlled clinical trial
10
A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose
10
IMMUNIZATION WITH INACTIVATED MEASLES VIRUS VACCINE: EFFECT OF BOOSTER DOSE AND RESPONSE TO NATURAL CHALLENGE
13
Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy
11
A Booster Dose for Hepatitis B Vaccine should be Recommended by EPI in Saudi Arabia at Adolescence and Young Adulthood
8
Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine
10
Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care students
6
Haemophilus influenzae Type b Disease and Vaccine Booster Dose Deferral, United States, 1998–2009
9
Diphtheria and Tetanus Antibody Persistence in Indian Pre school Children and Response to a Booster Dose of DT Vaccine
5
POLICY STATEMENT Meningococcal Conjugate Vaccines Policy Update: Booster Dose Recommendations
8
Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination
7
Adverse Reactions and Serologic Response to a Booster Dose of Acellular Pertussis Vaccine in Children Immunized With Acellular or Whole-Cell Vaccine as Infants
8
Timing of Booster Dose of Antipoliomyelitic Vaccine
7
Responses to a Conjugate Pneumococcal Vaccine in Preterm Infants Immunized at 2, 3, and 4 Months of Age
7
Immunogenicity of a Heptavalent Conjugate Pneumococcal Vaccine Administered Concurrently with a Combination Diphtheria, Tetanus, Five-Component Acellular Pertussis, Inactivated Polio, and Haemophilus influenzae Type b Vaccine and a Meningococcal Group C Conjugate Vaccine at 2, 3, and 4 Months of Age
6
Randomized, Open-Label Study of the Impact of Age on Booster Responses to the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Children in India
9
The seroepidemiology of pertussis in NSW: fluctuating immunity profiles related to changes in vaccination schedules
6
Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules
13
Seroimmunity to Tetanus and Diphtheria among Immunocompetent Adult Patients Admitted to a Tertiary Hospital for Any Reason
9